News

The study found that in one out of four instances, listed companies paid royalty to related parties (RPs) exceeding 20% of their net profits.

SOBHA Q2 Results | EBITDA was up 2.3% to ₹77 crore while the EBITDA margin fell to 8.3%. Shares of Sobha Ltd ended at ₹1,533.95, down by ₹11.55, or 0.75%, on the BSE.

This steady PPI figure is encouraging for the US dollar, as the alignment with expectations suggests a stable inflation rate. Such consistency supports a balanced economic outlook, which often strengthens the dollar by reinforcing confidence in the currency’s stability.

Post Content

The merger integrates Viacom18’s media and JioCinema businesses into Star India Private Ltd (SIPL), forming a new joint venture. Nita Ambani will be the chairperson of the JV, with Uday Shankar, as vice chairperson, providing strategic guidance to the JV. Shares of Reliance Industries Ltd ended at ₹1,267.70, up by ₹15.45, or 1.23%, on the BSE.

Zomato informed its investors that the fundraise is meant to strengthen its balance sheet at this point and that there is also no plan for any minority investments or acquisitions.

Speaking at CNBC-TV18’s Global Leadership Summit in Mumbai on Thursday, November 14, Chambers stated, ‘India will become the number one economy in the world, and it will be the fastest growing,’ underscoring the vast potential for economic expansion in a country with 1.4 billion people. Chambers also pointed to the warm diplomatic relationship between PM Modi and US President-elect Donald Trump, which he believes will fuel further growth.

Easy Trip Planners Q2 | The EBITDA margin stood at 25.5% in the reporting quarter versus 45.6% in the Q2 FY24. Shares of Easy Trip Planners Ltd ended at ₹30.13, up by ₹0.070, or 0.23%, on the BSE.

India’s largest two-wheeler manufacturer, Hero MotoCorp, reported a 14.2% year-on-year (YoY) increase in net profit to ₹1,203.5 crore for the September quarter, exceeding analysts’ expectations.

Glenmark Pharma Q2 Results | The company posted a net profit of ₹354.4 crore. EBITDA surged 30.2% to ₹601.7 crore over ₹462 crore in the year-ago period. Shares of Glenmark Pharmaceuticals Ltd ended at ₹1,539, up by ₹0.50, or 0.032%, on the BSE.